2-氨基-4-甲基-噁唑 | 35629-70-0

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2-氨基-4-甲基-噁唑
• 中文别名: 2-氨基-4-甲基恶唑；4-甲基-1,3-恶唑-2-胺；2-氨基-4-甲基-1,3-恶唑；2-氨基-4-甲基噁唑
• 英文名称: 2-amino-4-methyloxazole
• 英文别名: 2-Amino-4-methyloxazol；4-methyloxazol-2-amine；4-methyl-1,3-oxazol-2-amine；4-methyl-1,3-oxazole-2-amine；4-methyl-2-amino-oxazole
• CAS: 35629-70-0
• 化学式: C₄H₆N₂O
• mdl: MFCD00126682
• 分子量: 98.1044
• InChiKey: VCZJVXLWQTXSPQ-UHFFFAOYSA-N

物化性质

• 沸点：
  67-69°C 0,5mm
• 密度：
  1.1890 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  7
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  52
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 海关编码：
  2934999090
• 安全说明：
  S26,S36/37/39
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302
• 储存条件：
  库房应保持通风、低温和干燥的环境。

SDS

Name:	4-Methyl-1 3-oxazol-2-amine tech Material Safety Data Sheet
Synonym:
CAS:	35629-70-0

Section 1 - Chemical Product MSDS Name:4-Methyl-1 3-oxazol-2-amine tech Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
35629-70-0	4-Methyl-1,3-oxazol-2-amine		unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 35629-70-0: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: colorless - yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C4H6N2O
Molecular Weight: 98

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents, reducing agents, bases, acid chlorides.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 35629-70-0 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-Methyl-1,3-oxazol-2-amine - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 35629-70-0: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 35629-70-0 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 35629-70-0 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

类别：爆炸物品

爆炸物危险特性： 与双氧水和二价铁盐反应可发生爆炸。

可燃性危险特性： 可燃；燃烧时产生有毒氮氧化物烟雾。

储运特性： 应存放在通风、低温和干燥的库房中。

灭火剂： 使用干粉、泡沫、砂土、二氧化碳或雾状水进行灭火。

反应信息

• 作为反应物：
  描述：

  2-氨基-4-甲基-噁唑 生成 N-(4-甲基-2-恶唑基)-乙酰胺
  参考文献：
  名称：

  COCKERILL A. F.; DEACON A.; HARRISON R. G.; OSBORNE D. J.; PRIME D. M.; R+, SYNTHESIS , 1976 NO 9, 591-593

  摘要：

  DOI：
• 作为产物：
  描述：

  氰胺 、 羟基丙酮 在 ammonium hydroxide 作用下， 以 甲醇 、 水 为溶剂， 生成 2-氨基-4-甲基-噁唑
  参考文献：
  名称：

  17β-（2-氨基-恶唑-4-基）-甾族化合物的合成

  摘要：

  在氨的甲醇水溶液中，氰胺与皮质类固醇的20-氧代-21-羟基侧链反应，得到标题化合物。

  DOI：

  10.1039/p19750001999

文献信息

• Substituted 1-aryl-3-heteroaryl-thioureas (or isothioureas) as antiatherosclerotic agents
  申请人：Wyeth

  公开号：US06455566B1

  公开（公告）日：2002-09-24

  Antiatherosclerotic agents are provided which are represented by Formulas I or II: wherein R is  wherein R9, R10, R11, R12, R13, and R14 are each, independently, hydrogen or a lower alkyl of 1-6 carbon atoms; R6, and R7 are each, independently, hydrogen, lower alkyl of 1-6 carbon atoms, or CH2COOR8, where R8 is a lower alkyl of 1-6 carbon atoms; and X is O or S; R1 is hydrogen or a lower alkyl of 1-6 carbon atoms; R2, R3, and R4 are each, independently, hydrogen or halogen; and R5 is a lower alkyl of 1-6 carbon atoms; or a pharmaceutically acceptable salt thereof.

  提供了代表为Formula I或II的抗动脉粥样硬化药物： 其中 R为 其中R9、R10、R11、R12、R13和R14分别独立地为氢或1-6个碳原子的较低烷基； R6和R7分别独立地为氢、1-6个碳原子的较低烷基或CH2COOR8，其中R8为1-6个碳原子的较低烷基；以及 X为O或S； R1为氢或1-6个碳原子的较低烷基； R2、R3和R4分别独立地为氢或卤素；以及 R5为1-6个碳原子的较低烷基； 或其药用可接受盐。
• NITROGENOUS HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, COMPOSITION AND USE
  申请人：Shanghai Pharmaceuticals Holding Co., Ltd.

  公开号：EP3424928A1

  公开（公告）日：2019-01-09

  Disclosed are a nitrogenous heterocyclic compound, intermediates, a preparation method, a composition and use thereof. The nitrogenous heterocyclic compound in the present invention is as shown in formula I. The compound has a high inhibitory activity towards ErbB2 tyrosine kinase and a relatively good inhibitory activity towards human breast cancer BT-474 and human gastric cancer cell NCI-N87 which express ErbB2 at a high level, and at the same time has a relatively weak inhibitory activity towards EGFR kinase. Namely, the compound is a highly selective small-molecule inhibitor targeted at ErbB2, and hence it has a high degree of safety, and can effectively enlarge the safety window in the process of taking the drug.

  本公开揭示了一种含氮杂环化合物、中间体、制备方法、组合物及其用途。本发明中的含氮杂环化合物如公式I所示。该化合物对ErbB2酪氨酸激酶具有较高的抑制活性，并且对人类乳腺癌BT-474和人类胃癌细胞NCI-N87表达ErbB2的抑制活性相对较好，同时对EGFR激酶具有相对较弱的抑制活性。换句话说，该化合物是一种高度选择性的针对ErbB2的小分子抑制剂，因此具有很高的安全度，并且可以有效地扩大服药过程中的安全窗口。
• [EN] PYRROLO [2,3-B]PYRIDINE-3-CARBOXAMIDE COMPOSITIONS AND METHODS FOR AMELIORATING HEARING LOSS<br/>[FR] COMPOSITIONS DE PYRROLO [2,3-B] PYRIDINE-3-CARBOXAMIDE ET PROCÉDÉS POUR AMÉLIORER LA PERTE AUDITIVE
  申请人：GNEDEVA KSENIA

  公开号：WO2021158936A1

  公开（公告）日：2021-08-12

  N-(3-Substituted thiazol-2(3H)-ylidene)-1H-pyrrolo[2,3-b]pyridine-3-carboxamides and N-(3-substituted oxazol-2(3H)-ylidene)-1H-pyrrolo[2,3-b]pyridine-3-carboxamides (I) and (II) are disclosed. The compounds activate Yap and inhibit Lats kinases. They are therefore useful for treating hearing loss.

  N-(3-取代噻唑-2(3H)-基)-1H-吡咯并[2,3-b]吡啶-3-羧酰胺和N-(3-取代噁唑-2(3H)-基)-1H-吡咯并[2,3-b]吡啶-3-羧酰胺（I）和（II）已被披露。这些化合物激活Yap并抑制Lats激酶。因此，它们对治疗听力损失是有用的。
• Regioselective Friedel−Crafts Alkylation of Anilines and Amino-Substituted Heteroarenes with Hexafluoroacetone Sesquihydrate
  作者：Raffaello Masciadri、Matthias Kamer、Nadine Nock

  DOI：10.1002/ejoc.200300501

  日期：2003.11

  aminopyridines, underwent regioselective Friedel−Crafts alkylation in neat hexafluoroacetone sesquihydrate in a broad range of temperatures, reaction times, and yields (2%−94%) depending strongly on the electron density of the substrate. Prior N,N-dibenzylation of aniline and 2-aminopyridine strongly promoted substrate reactivity and resulted in higher yields (> 80%). The described Friedel−Crafts alkylations in

  各种芳烃，包括苯胺、吡咯、吲哚、氨基恶唑、氨基噻唑、氨基喹啉和氨基吡啶，在纯六氟丙酮倍半水合物中在广泛的温度、反应时间和产率 (2%−94%) 中进行区域选择性 Friedel-Crafts 烷基化很大程度上取决于基板的电子密度。苯胺和 2-氨基吡啶的先前 N,N-二苄基化强烈促进底物反应性并导致更高的产率 (> 80%)。六氟丙酮倍半水合物中所描述的 Friedel-Crafts 烷基化发生在苯胺的对位或杂芳烃中 sp2 杂化氮原子的 β 位置。(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2003)
• [EN] PYRAZOLE DERIVATIVES USEFUL AS 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS<br/>[FR] DÉRIVÉS DE PYRAZOLE UTILES EN TANT QU'INHIBITEURS (FLAP) DE PROTÉINE ACTIVANT LA 5-LIPOXYGÉNASE
  申请人：ASTRAZENECA AB

  公开号：WO2016177703A1

  公开（公告）日：2016-11-10

  The present application relates to novel compounds of formula (I) to their utility in treating and/or preventing clinical conditions including cardiovascular diseases (CVD), to methods for their therapeutic use, to pharmaceutical compositions containing them and to processes for preparing such compounds.

  本申请涉及到式(I)的新化合物，以及它们在治疗和/或预防心血管疾病（CVD）等临床疾病方面的用途，以及它们的治疗用途方法，含有它们的药物组合物以及制备这些化合物的过程。